design of a phase i trial of allogeneic anti-cd123 car t-cells in r/r aml
Published 3 years ago • 104 plays • Length 2:20Download video MP4
Download video MP3
Similar videos
-
3:41
preliminary results from phase i study of cd123 car-t therapy in pediatric r/r aml
-
3:33
allogeneic cd123-targeting car t-cell for aml: risks and potential
-
4:41
novel treatment approaches in bpdcn: the promise of cd123-targeting allogeneic car-t cells
-
2:19
first-in-human phase i trial of at101, a novel anti-cd19 car-t, in r/r nhl
-
1:26
preclinical safety and efficacy of cd123-nk cell engager in r/r aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
19:56
ξυπναμε μαζι ξεκιναμε μαζι γ μεροσ γ. χατζαριδησ & ε. γαβριηλακη 21-11-2019
-
13:06
e-motion motor tf adaptive simplified
-
48:45
ich m4-3. ectd around the world
-
2:48
ameli-01: safety and efficacy of ucart123v1.2 in r/r aml
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
2:19
anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
-
2:29
epitope editing enables the use of novel immunotherapies for aml
-
1:47
individualized machine learning predictions of allosct outcomes in aml: the harmony platform
-
3:52
a phase ii study evaluating the safety and efficacy of olutasidenib in patients with r/r midh1 aml
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
1:02
the use of car-t cell products in a real-world setting
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml